Research and Markets has announced the addition of the "Myocarditis - Pipeline Review, H2 2016" report to their offering.
Myocarditis pipeline therapeutics constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by Companies and remaining by the Universities Institutes.
Our latest report Myocarditis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue.
Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body. The molecules developed by Companies in Preclinical stages are 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/m45xmg/myocarditis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161011005850/en/Business Wire
Last updated on: 11/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.